Targeting mTOR in Glioblastoma: Rationale and PreclinicalClinical Evidence
Joint Authors
Mecca, Carmen
Giambanco, Ileana
Donato, Rosario
Arcuri, Cataldo
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-18
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
The mechanistic target of rapamycin (mTOR) drives several physiologic and pathologic cellular processes and is frequently deregulated in different types of tumors, including glioblastoma (GBM).
Despite recent advancements in understanding the molecular mechanisms involved in GBM biology, the survival rates of this tumor are still disappointing, primarily due to the lack of efficacious treatments.
The phosphatase and tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mTOR pathway has emerged as a crucial player in GBM development and progression.
However, to date, all the attempts to target this pathway with PI3K, AKT, or mTORC1 inhibitors failed to improve the outcome of patients with GBM.
Despite these discouraging results, recent evidence pointed out that the blockade of mTORC2 might provide a useful therapeutic strategy for GBM, with the potential to overcome the limitations that mTORC1 inhibitors have shown so far.
In this review, we analyzed the rationale of targeting mTOR in GBM and the available preclinical and clinical evidence supporting the choice of this therapeutic approach, highlighting the different roles of mTORC1 and mTORC2 in GBM biology.
American Psychological Association (APA)
Mecca, Carmen& Giambanco, Ileana& Donato, Rosario& Arcuri, Cataldo. 2018. Targeting mTOR in Glioblastoma: Rationale and PreclinicalClinical Evidence. Disease Markers،Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1153767
Modern Language Association (MLA)
Mecca, Carmen…[et al.]. Targeting mTOR in Glioblastoma: Rationale and PreclinicalClinical Evidence. Disease Markers No. 2018 (2018), pp.1-10.
https://search.emarefa.net/detail/BIM-1153767
American Medical Association (AMA)
Mecca, Carmen& Giambanco, Ileana& Donato, Rosario& Arcuri, Cataldo. Targeting mTOR in Glioblastoma: Rationale and PreclinicalClinical Evidence. Disease Markers. 2018. Vol. 2018, no. 2018, pp.1-10.
https://search.emarefa.net/detail/BIM-1153767
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1153767